Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Kremer LASIK PMA

This article was originally published in The Gray Sheet

Executive Summary

Kremer LASIK PMA: Ophthalmologist and inventor Fredric Kremer's premarket approval application for single-site use of an excimer laser to perform Laser-K LASIK (laser in situ keratomileusis) procedures is scheduled for review by FDA's Ophthalmic Devices Panel on Feb. 13. Approval of the PMA, which encompasses treatment of myopia and myopic astigmatism at Kremer Laser Eye Center, in King of Prussia, Pennsylvania, would seal an agreement with LaserSight giving the company rights to the technology ("The Gray Sheet" Aug. 18, 1997, I&W-16). The Kremer PMA is not the first single-site LASIK PMA to go before the panel. In July 1997, the Ophthalmic panel unanimously recommended approval of a PMA from The Vision Correction Group, Atlanta ("The Gray Sheet" July 21, 1997, p. 10)...

You may also be interested in...

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts